Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GNAO1 | P09471 | 12/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27315646 | 0.98 | CYP1A2 (0.56) | CYP1A2GNAO1GNAI3GNAI1LMNA | |
| Hydrochloric Acid SCHEMBL851007 | 0.98 | GNAO1 (0.58) | CYP1A2GNAO1GNAI3GNAI1LMNA | |
| Benzene SCHEMBL27520261 | 0.93 | CYP1A2 (0.52) | CYP1A2GNAO1GNAI3GNAI1LMNA | |
| SCHEMBL1368752 | 0.93 | GNAO1 (0.58) | CYP1A2GNAO1GNAI3GNAI1HRH3 | |
| SCHEMBL21284609 | 0.91 | CYP1A2 (0.61) | CYP1A2GNAO1GNAI3GNAI1LMNA | |
| Hydrochloric Acid SCHEMBL7645440 | 0.91 | GNAO1 (0.61) | CYP1A2GNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL5494333 | 0.91 | GNAO1 (0.61) | CYP1A2GNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL7345197 | 0.91 | GNAO1 (0.61) | CYP1A2GNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL9384220 | 0.91 | GNAO1 (0.61) | CYP1A2GNAO1GNAI3GNAI1ITGB3 | |
| SCHEMBL9388856 | 0.91 | GNAO1 (0.61) | CYP1A2GNAO1GNAI3GNAI1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019203427-A1 | CHELATING AGENT HAVING EXCELLENT PROPERTY OF SELECTIVELY FORMING COMPLEX WITH SPECIFIC METAL ION, AND PRODUCTION METHOD THEREFOR | (주)이엠티 | 2019-10-24 | — | — | WO | claimed |
| CN-110358353-A | A kind of ultraviolet light solidification optical fiber coloring ink composition and its application | 浙江瑞通光电材料有限公司 | 2019-10-22 | — | — | CN | claimed |
| US-10067266-B2 | Method of producing resin for thiourethane-based optical material using general-purpose polyisocyanate compound, resin composition for thiourethane-based optical material and thiourethane-based optical material including resin produced by the method | KOC SOLUTION CO., LTD. (KR) | 2018-09-04 | — | — | US | claimed |
| CN-103108918-B | Method for manufacturing resin for thiourethane-based optical material using universal polyisocyanate compound, resin composition, and optical material manufactured thereby | KOC SOLUTION CO LTD | 2015-07-15 | — | — | CN | claimed |
| CN-103108918-A | Method for manufacturing resin for thiourethane-based optical material using universal polyisocyanate compound, resin composition, and optical material manufactured thereby | KOC SOLUTION CO LTD | 2013-05-15 | — | — | CN | claimed |
| CN-102558026-A | Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1) | CGENE TECH SUZHOU CHINA CO LTD | 2012-07-11 | — | — | CN | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-0539281-B1 | Naphthamides, process for their preparation and their application in the therapeutical field | INST NAT SANTE RECH MED (FR) | 1998-12-30 | — | — | EP | claimed |
| US-5484949-A | Method for the synthesis of α β-unsaturated ketones | NIPPON SODA CO., LTD. (JP) | 1996-01-16 | — | — | US | claimed |
| EP-4472956-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | Bristol-Myers Squibb Company (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118660875-A | Protein tyrosine phosphatase inhibitors, compositions, and methods of use | 百时美施贵宝公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-0604494-A1 | 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-06 | — | — | EP | disclosed |
| EP-0454867-A1 | A METHOD FOR THE SYNTHESIS OF -g(a), -g(b)-UNSATURATED KETONES. | NIPPON SODA CO (JP) | 1991-11-06 | — | — | EP | disclosed |
| WO-1991007370-A1 | A METHOD FOR THE SYNTHESIS OF α, β-UNSATURATED KETONES | NIPPON SODA CO., LTD. (JP) | 1991-05-30 | — | — | WO | disclosed |
| EP-0225886-A1 | NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM. | CHEMIE LINZ AG (AT) | 1987-06-24 | — | — | EP | disclosed |
| WO-1986006719-A1 | NEW PYRIDAZINE COMPOSITIONS, PRODUCTION PROCESS THEREOF AND FUNGICIDES AND ALGICIDES CONTAINING THEM | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | CYP1A2 612/4885GNAO1 766/4885GNAI3 1830/4885 |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | PTPN2, PTPN22, PTPN5 | CYP1A2 735/4885GNAO1 1184/4885GNAI3 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.